Entries |
Document | Title | Date |
20080207721 | Chemical compounds - Compounds of formula (I): | 08-28-2008 |
20090023795 | Kinase Inhibitors And Methods Of Use Thereof - The compound of Formula (I) and pharmaceutically acceptable salts and prodrugs thereof are useful in the treatment and prevention of various disorders mediated by kinases. | 01-22-2009 |
20090042966 | Mitotic Kinesin Inhibitors - The present invention relates to fluorinated dihydropyrazole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals. | 02-12-2009 |
20090118344 | Crystalline Chemotherapeutic - N-[4-(3-Amino-1H-indazol-4-yl)phenyl]-N′-(2-fluoro-5-methylphenyl)urea Hydrate Crystalline Form 1, ways to make it, formulations comprising it and made with it and methods of treating patients having disease using it are disclosed. | 05-07-2009 |
20090118345 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES - The present invention provides novel pyrazoles that are useful as cannabinoid receptor antagonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, hepatic disorders, and/or cardiometabolic disorders. | 05-07-2009 |
20090312385 | CANNABINOID RECEPTOR MODULATORS FOR TREATING NON-IMMEDIATE TYPE ALLERGIC DISEASES - The present invention relates to the use of cannabinoid receptor modulators, particularly selective CB2 receptor agonists, for treating non-immediate type allergic diseases in mammals. The invention further relates to a pharmaceutical composition for non-immediate type allergic diseases. | 12-17-2009 |
20100041725 | STABLE PHARMACEUTICAL COMPOSITION - A pharmaceutical composition comprising a compound represented by the general formula (I): | 02-18-2010 |
20100105751 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES - The present invention provides novel pyrazoles that are useful as cannabinoid receptor antagonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, hepatic disorders, and/or cardiometabolic disorders. | 04-29-2010 |
20100190836 | Compounds, Screens, and Methods of Treatment - The present invention features compounds, pharmaceutical compositions, and methods for treating trauma, ischemia, stroke, degenerative diseases associated with cellular necrosis, and other conditions. Screening assays for identifying compounds useful for treating these conditions are also described. | 07-29-2010 |
20100249203 | COMPOUNDS THAT INHIBIT TRPV1 AND USES THEREOF - Compounds of formula (I) | 09-30-2010 |
20120004274 | USE OF INHIBITORS OF JUN N-TERMINAL KINASES TO TREAT GLAUCOMA - Compositions and methods for lowering IOP and/or providing neuroprotection are disclosed. The compositions and methods are particularly directed to the use inhibitors of Jun N-terminal kinases (JNK) to lower IOP and/or provide neuroprotection. | 01-05-2012 |
20120264797 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES - The present invention provides novel pyrazoles that are useful as cannabinoid receptor antagonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, hepatic disorders, and/or cardiometabolic disorders. | 10-18-2012 |
20130345277 | Modulators of GTPase and Use In Relevant Treatment - The present invention relates to molecules which function as selective modulators of the Ras-homologous (Rho) family of small GTPases, in particular, Cdc42 GTPase and their use to treat diseases, for example cancers, including metastatic cancer, genetic and acquired diseases where activation of Cdc42 GTPase plays a pivotal role, such as neurodegenerative diseases, rheumatoid arthritis, atherosclerosis, diabetes type I, autosomal polycystic kidney disease, cystic kidney disease, precystic kidney disease, microbial infections, including | 12-26-2013 |
20140031404 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING DISEASE CONDITIONS, INCLUDING METABOLIC DISORDERS AND CANCERS - The present invention provides novel, diastereomeric pyrazolines that are useful as cannabinoid receptor blockers and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, inflammatory disorders, cardiometabolic disorders, hepatic disorders, and/or cancers. | 01-30-2014 |
20140163082 | PYRAZOLYL COMPOUNDS FOR USE IN REVERSING REACTIVE GLIOSIS - The present invention refers to a compound which is a pyrazolyl compound for use as a medicament in a neurodegenerative disease or disorder, preferably reactive gliosis. Also, a pyrazolyl compound that is 3-(5′-hydroxymethyl-2′-furyl)-1-benzylindazole (YC-1) for use as a medicament in a disease or disorder, preferably for the treatment, reversal or the attenuation of reactive gliosis, and/or reactive gliosis directly or indirectly associated with an eye disease, disease of the retina, or retinal disorder. Further, the invention discloses pharmaceutical compositions thereof and a method for treating a neurodegenerative disorder, preferably reactive gliosis, comprising administering to a subject in need thereof an effective amount of such compound or pharmaceutical composition. | 06-12-2014 |
20140171477 | DERIVATIVES OF CELEBOXIB, USE THEREOF AND PREPARATION THEREOF - Derivatives of celecoxib that lack cyclooxygenase inhibitory activity but have improved PDE5 inhibitory activity are provided along with pharmaceutical compositions containing them for the treatment or prevention of cancer. Such compounds are expected to have reduced toxicity compared with celecoxib and other cyclooxygenase inhibitors, and greater efficacy compared with conventional PDE5 inhibitors. Derivatives of celecoxib are also suitable for treating chronic inflammatory conditions, erectile dysfunction, pulmonary hypertension, congestive heart failure, and enhancement of cognitive function. | 06-19-2014 |
20140329875 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FORTREATING DISEASE CONDITIONS, INCLUDING METABOLIC DISORDERS ANDCANCERS - The present invention provides novel, diastereomeric pyrazolines that are useful as cannabinoid receptor blockers and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, inflammatory disorders, cardiometabolic disorders, hepatic disorders, and/or cancers. | 11-06-2014 |
20160058736 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES - The present invention provides novel, diastereomeric pyrazolines that are useful as cannabinoid receptor blockers and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, inflammatory disorders, cardiometabolic disorders, hepatic disorders, and/or cancers. | 03-03-2016 |
20170231961 | PYRAZOLINE-DERIVED COMPOUND AND ITS USE IN A WEEKLY DOSAGE REGIME AGAINST INFLAMMATION AND PAIN DERIVED FROM DEGENERATIVE JOINT DISEASE IN MAMMALS | 08-17-2017 |
20190142802 | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | 05-16-2019 |